HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

LPAA

Launch One Acquisition Corp

Last Close
Feb 06  •  04:00PM ET
10.73
Dollar change
+0.09
Percentage change
0.85 %
Financial • Shell Companies • USA • NASD
Held by: SPCZ
Scroll to Statements
Index- P/E35.11 EPS (ttm)0.31 Insider Own20.00% Shs Outstand23.00M Perf Week0.94%
Market Cap306.76M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float23.00M Perf Month1.23%
Enterprise Value306.66M PEG- EPS next Q- Inst Own86.30% Short Float0.01% Perf Quarter1.90%
Income8.79M P/S- EPS this Y- Inst Trans- Short Ratio0.04 Perf Half Y3.07%
Sales0.00M P/B1.33 EPS next Y- ROA3.68% Short Interest0.00M Perf YTD1.32%
Book/sh8.06 P/C3067.60 EPS next 5Y- ROE3.86% 52W High10.70 0.28% Perf Year6.93%
Cash/sh0.00 P/FCF- EPS past 3/5Y- - ROIC3.79% 52W Low10.09 6.34% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility0.19% 0.14% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM- Oper. Margin- ATR (14)0.02 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.54 Sales Y/Y TTM- Profit Margin- RSI (14)78.16 Recom-
Dividend Gr. 3/5Y- - Current Ratio0.54 EPS Q/Q-22.74% SMA200.86% Beta0.01 Target Price-
Payout0.00% Debt/Eq0.00 Sales Q/Q- SMA501.25% Rel Volume0.00 Prev Close10.64
Employees- LT Debt/Eq0.00 Earnings- SMA2002.59% Avg Volume34.79K Price10.73
IPOSep 03, 2024 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume4 Change0.85%
Jan-13-26 10:15AM
Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform
(GlobeNewswire)
Nov-20-25 08:30AM
Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition
(GlobeNewswire)
Oct-15-25 07:30AM
Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome
(GlobeNewswire)
Sep-18-25 07:30AM
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
(GlobeNewswire)
Aug-27-25 07:15AM
Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers
(GlobeNewswire)
08:15AM Loading…
Jul-24-25 08:15AM
Minovia Therapeutics Announces Interim Data from Phase 2 Trial in Pearson Syndrome Demonstrating No Treatment-Related Serious Adverse Events and Preliminary Signal for Efficacy Measured by Growth
(GlobeNewswire)
Jun-30-25 08:30AM
Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome
(GlobeNewswire)
Jun-25-25 08:30AM
Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets
(GlobeNewswire)
Launch One Acquisition Corp. is a blank check company, which engages for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on February 21, 2024 and is headquartered in Oakland, CA.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.